替吉奥联合奥沙利铂与改良FOLFOX6方案一线治疗进展期胃癌的随机对照研究

宋金成, 张弦, 张阳

宋金成, 张弦, 张阳. 替吉奥联合奥沙利铂与改良FOLFOX6方案一线治疗进展期胃癌的随机对照研究[J]. 实用临床医药杂志, 2013, (3): 63-65. DOI: 10.7619/jcmp.201303020
引用本文: 宋金成, 张弦, 张阳. 替吉奥联合奥沙利铂与改良FOLFOX6方案一线治疗进展期胃癌的随机对照研究[J]. 实用临床医药杂志, 2013, (3): 63-65. DOI: 10.7619/jcmp.201303020
SONG Jincheng, ZHANG Xian, ZHANG Yang. Randomized controlled trial on S-1 combined with oxaliplatin and modified FOLFOX6 in the first-line therapy of advanced gastric cancer[J]. Journal of Clinical Medicine in Practice, 2013, (3): 63-65. DOI: 10.7619/jcmp.201303020
Citation: SONG Jincheng, ZHANG Xian, ZHANG Yang. Randomized controlled trial on S-1 combined with oxaliplatin and modified FOLFOX6 in the first-line therapy of advanced gastric cancer[J]. Journal of Clinical Medicine in Practice, 2013, (3): 63-65. DOI: 10.7619/jcmp.201303020

替吉奥联合奥沙利铂与改良FOLFOX6方案一线治疗进展期胃癌的随机对照研究

基金项目: 中国高校医学期刊临床专项资金
详细信息
  • 中图分类号: R735.2

Randomized controlled trial on S-1 combined with oxaliplatin and modified FOLFOX6 in the first-line therapy of advanced gastric cancer

  • 摘要: 目的 比较国产替吉奥联合奥沙利铂方案(SOx)与改良FOLFOX6方案(mFOLFOX6)一线治疗局部晚期或转移性胃癌的近期疗效、远期生存及安全性.方法 40例进展期胃癌患者随机分为A、B组,A组采用SOX联合化疗方案,B组采用mFOLFOX6方案.2组患者均接受至少2周期化疗,每2周期评判1次近期疗效.结果 A组客观有效率、疾病控制率、中位疾病进展时间、中位生存期、1年生存率分别为45.0%、80.0%、6.0个月、15.0个月和45.0%;B组分别为40.0%、90.0%、5.5个月、11.0个月和35.0%.2组客观有效率及生存期无显著差异.2组不良反应均为血液系统毒性、恶心/呕吐和外周神经毒性,A组不良反应整体略轻微,但无显著性差异.结论 氟尿嘧啶类药物联合奥沙利铂一线治疗进展期胃癌有较好的近期和远期疗效;替吉奥口服与氟尿嘧啶静脉化疗在疗效上无显著差异,不良反应均可耐受,可根据患者个体状况选择应用.
  • 秦叔逵, 龚新雷. 晚期胃癌化疗的现状和新进展 [J]. 临床肿瘤学杂志, 2006(9):641.doi: 10.3969/j.issn.1009-0460.2006.09.001.
    Van Cutsemn E, Moiseyenko V M, Tjulandin S. Phase Ⅲ study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer.:a report of the V325 Study Group [J]. Journal of Clinical Oncology, 2006, (31):4991.
    Cunningharn D, Starling N, Rao S. Capecitabine and oxaliplatin for advanced esoplagogastric cance [J]. New England Journal of Medicine, 2008(1):36.
    Kang Y K, Kang W K, Shin D B. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer:a randomized phase Ⅲ non-inferiority trial [J]. Annals of Oncology, 2009(4):666.
    严冬, 戴红. FOLFOX方案治疗局部进展期或转移性胃癌 [J]. 中华肿瘤杂志, 2009(3):217.doi: 10.3760/cma.j.issn.0253-3766.2009.03.015.
    袁梅琴, 钟海钧, 杨云山. S-1治疗进展期胃癌的研究进展 [J]. 国际肿瘤学杂志, 2011(4):289.doi: 10.3760/cma.j.issn.1673-422X.2011.04.015.
    Koizumi W, Narahara H, Hara T. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial):a phase Ⅲ trial [J]. Lancet Oncology, 2008(3):215.
    Ajani J A, Rodriguez W, Bodoky G. Multicenter phase Ⅲ comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophaageal adenocarcinoma study:the FLAGS trial [J]. Journal of Clinical Oncology, 2010(9):1547.
    邱国钦, 许丽贞, 林智才. 替吉奥联合顺铂治疗进展期胃癌的近期疗效观察 [J]. 临床肿瘤学杂志, 2011(8):728.doi: 10.3969/j.issn.1009-0460.2011.08.014.
    李小平, 郑磊贞, 章莉. 替吉奥联合顺铂与FOLFOX4方案治疗晚期胃癌的疗效比较 [J]. 肿瘤学杂志, 2012(3):230.
    李涛, 陈凛. SOX方案新辅助化疗应用于进展期胃癌的有效性和安全性研究 [J]. 中华胃肠外科杂志, 2011(2):104.doi: 10.3760/cma.j.issn.1671-0274.2011.02.009.
    董静波, 李雁, 翁国爱. 替吉奥联合奥沙利铂治疗进展期胃癌安全性评价 [J]. 肿瘤学杂志, 2011(4):253.
计量
  • 文章访问数:  186
  • HTML全文浏览量:  33
  • PDF下载量:  6
  • 被引次数: 0
出版历程
  • 发布日期:  2013-05-22

目录

    /

    返回文章
    返回